E-LIB Suche - Ergebnisse für: Madero, Juan Sierra

1

EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATA..:

Porteiro, Norma ; Cahn, Pedro ; Madero, Juan Sierra...
The Brazilian Journal of Infectious Diseases. 26 (2022) - p. 102125 , 2022

Link: https://doi.org/10.1016/..

2

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC..:

Cahn, Pedro ; Madero, Juan Sierra ; Arribas, José Ramón...
The Brazilian Journal of Infectious Diseases. 25 (2021) - p. 101259 , 2021

Link: https://doi.org/10.1016/..

3

Dolutegravir plus lamivudine versus dolutegravir plus tenof..:

Cahn, Pedro ; Madero, Juan Sierra ; Arribas, José Ramón...
The Lancet. 393 (2019) 10167 - p. 143-155 , 2019

Link: https://doi.org/10.1016/..

4

Maraviroc, as a Switch Option, in HIV-1–infected Individual..:

Pett, Sarah Lilian ; Amin, Janaki ; Horban, Andrejz...
Clinical Infectious Diseases. 63 (2016) 1 - p. 122-132 , 2016

Link: https://www.jstor.org/st..

5

Survival After Cancer Diagnosis in an HIV-Positive Populati..:

Fink, Valeria ; Jenkins, Cathy ; Castilho, Jessica...
Open Forum Infectious Diseases. 3 (2016) suppl_1 - p. , 2016

Link: https://doi.org/10.1093/..

6

Mortality and loss to follow‐up among HIV‐infected persons ..:

Carriquiry, Gabriela ; Fink, Valeria ; Koethe, John Robert...
Journal of the International AIDS Society. 18 (2015) 1 - p. , 2015

Link: https://doi.org/10.7448/..

7

Duration of Anti-Tuberculosis Therapy and Timing of Antiret..:

Cortes, Claudia P. ; Wehbe, Firas H. ; McGowan, Catherine C....
PLoS ONE. 8 (2013) 9 - p. e74057 , 2013

Link: https://doi.org/10.1371/..

8

Rates and Reasons for Early Change of First HAART in HIV-1-..:

Cesar, Carina ; Shepherd, Bryan E. ; Krolewiecki, Alejandro J....
PLoS ONE. 5 (2010) 6 - p. e10490 , 2010

Link: https://doi.org/10.1371/..

9

Relationship Between Anemia and Systemic Inflammation in Pe..:

Araújo-Pereira, Mariana ; Barreto-Duarte, Beatriz ; Arriaga, María B....
Frontiers in Immunology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

10

475. Describing the impact of the COVID-19 pandemic on HIV ..:

Person, Anna K ; Maruri, Fernanda ; Brazier, Ellen...
Open Forum Infectious Diseases. 7 (2020) Supplement_1 - p. S303-S304 , 2020

Link: https://doi.org/10.1093/..

11

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC ..:

Ait-Khaled, Mounir ; Man, Choy ; Sievers, Jorg...
Open Forum Infectious Diseases. 7 (2020) Supplement_1 - p. S541-S542 , 2020

Link: https://doi.org/10.1093/..

12

Three-year durable efficacy of dolutegravir plus lamivudine..:

Cahn, Pedro ; Sierra Madero, Juan ; Arribas, José R....
AIDS. 36 (2021) 1 - p. 39-48 , 2021

Link: https://doi.org/10.1097/..

13

Impact of treatment adherence on efficacy of dolutegravir p..:

Ait-Khaled, Mounir ; Sierra Madero, Juan ; Estrada, Vicente...
HIV Research & Clinical Practice. 23 (2021) 1 - p. 9-14 , 2021

Link: https://doi.org/10.1080/..

14

Maraviroc, as a Switch Option, in HIV-1–infected Individual..:

Pett, Sarah Lilian ; Amin, Janaki ; Horban, Andrejz...
Clinical Infectious Diseases. 63 (2016) 1 - p. 122-132 , 2016

Link: https://doi.org/10.1093/..

15

Changes in lipid levels after 48 weeks of dual versus tripl..:

Cahn, Pedro ; Andrade Villanueva, Jaime ; Arribas, Jose...
Journal of the International AIDS Society. 17 (2014) 4S3 - p. , 2014

Link: https://doi.org/10.7448/..